
Wednesday, November 18, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
NV-387 Began Two-Phase 2 Trials During 3Q26. NanoViricides reported a 3Q26 loss of $5.7 million, or $(0.23) per share. The increase over previous quarters was largely due to increased R&D expenses for the two Phase 2a trials that began testing NV-387 for Ebola and Mpox in the Democratic Republic of Congo (DRC). These trials are the most advanced testing of its effectiveness as an antiviral agent.
Ebola Phase 2a Trial Began In September. The Phase 2a trial testing NV-387 for treating Ebola Bundibugyo Virus (BDBV) disease began enrollment in late September 2026. As discussed in our Research Note on October 15, patients will receive NV-387 chewable solids (gummies) for 6 days, then be evaluated to determine whether the disease has stabilized or improved. Treatment may be continued for an additional 3 days, up to 12 days total.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.